HC Wainwright Reduces Earnings Estimates for Altimmune

Altimmune, Inc. (NASDAQ:ALT) – HC Wainwright reduced their FY2024 earnings estimates for shares of Altimmune in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($1.28) for the year, down from their previous forecast of ($1.25). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Altimmune’s Q1 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at ($1.45) EPS and FY2028 earnings at ($0.15) EPS.

Other equities analysts have also issued reports about the stock. UBS Group assumed coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target for the company. B. Riley reaffirmed a “buy” rating and issued a $20.00 target price on shares of Altimmune in a report on Monday, August 12th. Finally, Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Stock Down 6.0 %

ALT stock opened at $7.15 on Monday. The business’s 50-day moving average price is $7.04 and its 200-day moving average price is $6.91. The stock has a market cap of $508.54 million, a P/E ratio of -4.61 and a beta of 0.09. Altimmune has a twelve month low of $2.41 and a twelve month high of $14.84.

Altimmune (NASDAQ:ALT) last released its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million for the quarter. During the same quarter last year, the firm posted ($0.39) earnings per share.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC purchased a new stake in shares of Altimmune in the third quarter valued at $31,000. CANADA LIFE ASSURANCE Co purchased a new stake in Altimmune in the 1st quarter worth about $44,000. TFO Wealth Partners LLC bought a new stake in Altimmune in the first quarter worth about $51,000. Horizon Wealth Management LLC purchased a new position in shares of Altimmune during the second quarter valued at approximately $66,000. Finally, PFG Investments LLC bought a new position in shares of Altimmune during the second quarter valued at approximately $67,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.